Literature DB >> 15708732

Progressive morphometric and cognitive changes in vascular dementia.

John Gunstad1, Adam M Brickman, Robert H Paul, Jeffrey Browndyke, David J Moser, Brian R Ott, Norman Gordon, Omar Haque, Ronald A Cohen.   

Abstract

Evidence for progressive cognitive decline in vascular dementia (VaD) is mixed, with some studies showing little or no decline over time. One possible explanation for these inconsistent findings is the heterogeneity of pathology encompassed by the VaD diagnosis. It is possible that subtypes of VaD (i.e. those resulting from different lesion distributions) show different patterns of cognitive decline. In the present study, a heterogeneous VaD group demonstrated cognitive decline from baseline to 12-month follow-up. Although this decline was coincident to morphometric changes (i.e. increased subcortical hyperintensities (SH), decreased whole brain volume (WBV)), no relationship emerged between cognitive decline and morphometric changes. Preliminary examination of VaD subtypes revealed patients with subcortical infarct or SH-only exhibited greater decline than VaD patients with cortical lesions. Further research is needed to determine whether this observed decline is attributable to differential lesion distribution or statistical artifact.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15708732     DOI: 10.1016/j.acn.2004.07.001

Source DB:  PubMed          Journal:  Arch Clin Neuropsychol        ISSN: 0887-6177            Impact factor:   2.813


  4 in total

1.  Nigella sativa and thymoquinone attenuate oxidative stress and cognitive impairment following cerebral hypoperfusion in rats.

Authors:  Sahar Fanoudi; Mohaddeseh S Alavi; Mahmoud Hosseini; Hamid R Sadeghnia
Journal:  Metab Brain Dis       Date:  2019-04-23       Impact factor: 3.584

2.  Piracetam improves cognitive deficits caused by chronic cerebral hypoperfusion in rats.

Authors:  Zhi He; Yun Liao; Min Zheng; Fan-Dian Zeng; Lian-Jun Guo
Journal:  Cell Mol Neurobiol       Date:  2007-08-21       Impact factor: 5.046

3.  β-Caryophyllene/Hydroxypropyl-β-Cyclodextrin Inclusion Complex Improves Cognitive Deficits in Rats with Vascular Dementia through the Cannabinoid Receptor Type 2 -Mediated Pathway.

Authors:  Jie Lou; Zhipeng Teng; Liangke Zhang; Jiadan Yang; Lianju Ma; Fang Wang; Xiaocui Tian; Ruidi An; Mei Yang; Qian Zhang; Lu Xu; Zhi Dong
Journal:  Front Pharmacol       Date:  2017-01-19       Impact factor: 5.810

Review 4.  Citicoline (Cognizin) in the treatment of cognitive impairment.

Authors:  Mario Fioravanti; Ann E Buckley
Journal:  Clin Interv Aging       Date:  2006       Impact factor: 4.458

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.